JP2023517644A5 - - Google Patents
Info
- Publication number
- JP2023517644A5 JP2023517644A5 JP2022554681A JP2022554681A JP2023517644A5 JP 2023517644 A5 JP2023517644 A5 JP 2023517644A5 JP 2022554681 A JP2022554681 A JP 2022554681A JP 2022554681 A JP2022554681 A JP 2022554681A JP 2023517644 A5 JP2023517644 A5 JP 2023517644A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- composition
- mol
- nucleic acid
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987191P | 2020-03-09 | 2020-03-09 | |
| US62/987,191 | 2020-03-09 | ||
| US202063073900P | 2020-09-02 | 2020-09-02 | |
| US63/073,900 | 2020-09-02 | ||
| PCT/US2021/021572 WO2021183563A1 (en) | 2020-03-09 | 2021-03-09 | Coronavirus vaccine compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517644A JP2023517644A (ja) | 2023-04-26 |
| JP2023517644A5 true JP2023517644A5 (https=) | 2024-03-18 |
Family
ID=77671984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554681A Pending JP2023517644A (ja) | 2020-03-09 | 2021-03-09 | コロナウイルスワクチン組成物及び方法 |
| JP2022554368A Pending JP2023519173A (ja) | 2020-03-09 | 2021-03-09 | 免疫応答を誘導するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554368A Pending JP2023519173A (ja) | 2020-03-09 | 2021-03-09 | 免疫応答を誘導するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US11744887B2 (https=) |
| EP (2) | EP4117720A4 (https=) |
| JP (2) | JP2023517644A (https=) |
| AU (2) | AU2021236068A1 (https=) |
| CA (2) | CA3171231A1 (https=) |
| TW (1) | TW202200605A (https=) |
| WO (2) | WO2021183563A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US10526284B2 (en) * | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| AU2021236068A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| KR20220156933A (ko) | 2020-03-23 | 2022-11-28 | 에이치디티 바이오 코포레이션 | Rna의 전달을 위한 조성물 및 방법 |
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| EP4178545A4 (en) * | 2020-07-10 | 2024-08-07 | Engimata, Inc | IMMUNOGENIC COMPOSITION FORMING A VACCINE AND METHOD OF MANUFACTURE THEREOF |
| EP4196128A4 (en) | 2020-08-14 | 2024-06-12 | Arcturus Therapeutics, Inc. | METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES |
| SE544840C2 (en) * | 2020-09-28 | 2022-12-13 | Stora Enso Oyj | Method for the preparation of a bio-based carbon foam |
| EP4228658A4 (en) | 2020-10-14 | 2025-02-19 | George Mason Research Foundation, Inc. | IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| US20220356212A1 (en) * | 2021-03-26 | 2022-11-10 | Nanogen Pharmaceutical Biotechnology JSC | Modified spike protein and method of treatment |
| TW202313967A (zh) * | 2021-07-30 | 2023-04-01 | 美商亞克圖羅斯醫療公司 | Ｒｎａ疫苗 |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4404962A4 (en) * | 2021-09-20 | 2026-03-25 | Cyanvac Llc | PIV5-BASED CORONAVIRUS VACCINES AND THEIR METHODS OF USE |
| WO2023048760A1 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| CA3232719A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Sars-cov-2 rna vaccine compositions and methods of use |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| WO2023057979A1 (en) * | 2021-10-07 | 2023-04-13 | Precision NanoSystems ULC | Rna vaccine lipid nanoparticles |
| WO2023079472A2 (en) * | 2021-11-03 | 2023-05-11 | Kashiv Biosciences, Llc | Multicistron expression vector for covid-19 vaccine |
| AU2022381750A1 (en) * | 2021-11-03 | 2024-05-16 | Arcturus Therapeutics, Inc. | Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US11510975B1 (en) * | 2021-11-29 | 2022-11-29 | Replicate Bioscience, Inc. | Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses |
| WO2023097102A2 (en) * | 2021-11-29 | 2023-06-01 | Aegis Life, Inc. | Sars cov-2 vaccine, associated polynucleotides, and methods of use |
| US20250041238A1 (en) * | 2021-12-23 | 2025-02-06 | Etherna Immunotherapies Nv | METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs |
| CN118613493A (zh) * | 2022-01-05 | 2024-09-06 | 螺旋纳米技术公司 | 包含α-因子前原序列的组合物及其用途 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN116916891A (zh) * | 2022-02-07 | 2023-10-20 | Seqirus公司 | 自我复制rna和其用途 |
| CN116768987A (zh) * | 2022-03-09 | 2023-09-19 | 中生复诺健生物科技(上海)有限公司 | 编码新型冠状病毒S蛋白的mRNA疫苗 |
| EP4511497A4 (en) * | 2022-04-19 | 2026-04-22 | Replicate Bioscience Inc | MODIFIED WESTERN EQUINE ENCEPHALITIS VIRUS AND ITS USES |
| CN114557971B (zh) * | 2022-04-25 | 2023-05-23 | 康希诺生物股份公司 | 一种核酸-脂质纳米颗粒的冷冻干燥保护剂及其制备方法和应用 |
| CN119563028A (zh) * | 2022-05-12 | 2025-03-04 | 尚威天成信使核糖核酸治疗公司 | 具有分泌抗原和免疫调节物的合成自扩增mRNA分子 |
| WO2023221938A1 (zh) * | 2022-05-16 | 2023-11-23 | 上海行深生物科技有限公司 | 蛋白包裹自复制rna及其制备方法 |
| CA3256897A1 (en) * | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| US12186388B2 (en) * | 2022-11-02 | 2025-01-07 | Centre For Virology, Vaccinology And Therapeutics Limited | Interferon-producing universal sarbecovirus vaccines, and uses thereof |
| TW202438672A (zh) * | 2023-01-31 | 2024-10-01 | 美商亞克圖羅斯醫療公司 | 四價流感疫苗之方法及組成物 |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| AU2024279278A1 (en) * | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025104023A1 (en) * | 2023-11-13 | 2025-05-22 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| TW202539706A (zh) * | 2023-11-14 | 2025-10-16 | 大陸商上海瑞宏迪醫藥有限公司 | 一種脂質奈米粒的製備方法和應用 |
| GB202400648D0 (en) * | 2024-01-17 | 2024-02-28 | Uea Enterprises Ltd | Protein replacement therapy |
| WO2025189168A1 (en) * | 2024-03-08 | 2025-09-12 | SunVax mRNA Therapeutics Inc. | Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy |
| US20260002196A1 (en) * | 2024-07-01 | 2026-01-01 | New England Biolabs, Inc. | Programmable Cleavage of RNA |
| JP7657411B1 (ja) * | 2025-01-23 | 2025-04-07 | 医療法人すぎやま内科 | 乳がん細胞の増殖抑制剤及び乳がん治療剤 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2330202T5 (es) | 2001-09-06 | 2014-01-20 | Alphavax, Inc. | Sistemas vectores basados en replicones de alfavirus |
| US7442381B2 (en) | 2003-03-20 | 2008-10-28 | Alphavax, Inc. | Alphavirus replicons and helper constructs |
| CN1989250B (zh) | 2004-05-18 | 2013-11-20 | 阿尔法瓦克斯公司 | Tc-83衍生的甲病毒属载体、颗粒和方法 |
| EP2848692B1 (en) | 2004-05-21 | 2017-08-16 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| KR101499750B1 (ko) * | 2006-02-27 | 2015-03-06 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 가감염성 플라비바이러스 및 이들의 용도 |
| US8304529B2 (en) | 2006-07-28 | 2012-11-06 | Life Technologies Corporation | Dinucleotide MRNA cap analogs |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| US8460913B2 (en) | 2007-06-21 | 2013-06-11 | Alpha Vax, Inc. | Promoterless cassettes for expression of alpha virus structural proteins |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| AU2008338803B2 (en) * | 2007-11-26 | 2015-02-05 | Glaxosmithkline Biologicals S.A. | Methods of generating alphavirus particles |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| BRPI0913045A2 (pt) * | 2008-05-23 | 2017-05-23 | Fit Biotech Oy | vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| ES2647662T3 (es) | 2009-12-31 | 2017-12-26 | Medigen, Inc. | Vacunas de ADN infeccioso frente al virus chikungunya |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| EP2591114B1 (en) * | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| MX342608B (es) | 2010-07-06 | 2016-10-06 | Novartis Ag * | Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion. |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| SI4043040T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
| WO2012170431A2 (en) * | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| MX366055B (es) | 2011-08-31 | 2019-06-26 | Novartis Ag | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| WO2014170493A2 (en) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| EP3798229A1 (en) | 2014-03-25 | 2021-03-31 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| WO2016184822A1 (en) * | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
| CN120842296A (zh) | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| AU2016354102B2 (en) | 2015-11-09 | 2022-05-12 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| US12257352B2 (en) | 2016-06-20 | 2025-03-25 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2018010815A1 (en) * | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| KR102718353B1 (ko) | 2016-10-17 | 2024-10-15 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| CA3040337A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| JP2020500552A (ja) | 2016-11-23 | 2020-01-16 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のウイルスによる送達方法 |
| CA3045650A1 (en) | 2016-12-05 | 2018-06-14 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| WO2018119163A1 (en) * | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
| US10383952B2 (en) * | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| WO2018156617A2 (en) | 2017-02-22 | 2018-08-30 | The Regents Of The University Of Michigan | Compositions and methods for delivery of polymer / biomacromolecule conjugates |
| US11407800B2 (en) | 2017-02-28 | 2022-08-09 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| ES3039647T3 (en) | 2017-05-31 | 2025-10-23 | Arcturus Therapeutics Inc | Synthesis and structure of high potency rna therapeutics |
| BR112019025224A2 (pt) * | 2017-05-31 | 2020-12-08 | Ultragenyx Pharmaceutical Inc. | Terapêutica para doença de armazenamento de glicogênio tipo iii |
| CN111163799A (zh) | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
| WO2019121513A1 (en) | 2017-12-18 | 2019-06-27 | Intervet International B.V. | Swine influenza a virus vaccine |
| JP7494117B2 (ja) * | 2018-01-19 | 2024-06-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えレプリコン系を使用する免疫応答の誘導および増強 |
| WO2020014654A1 (en) | 2018-07-13 | 2020-01-16 | The Trustees Of Indiana University | Recombinant rotavirus expression system and recombinant rotaviruses |
| US12083174B2 (en) | 2018-08-17 | 2024-09-10 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| WO2020146700A1 (en) | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Lipid nanoparticles |
| SG11202110036RA (en) | 2019-03-19 | 2021-10-28 | Arcturus Therapeutics Inc | Method of making lipid-encapsulated rna nanoparticles |
| GB201908729D0 (en) | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| AU2020298267A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Self-replicating RNA molecules for hepatitis B virus (HBV) vaccines and uses thereof |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| WO2021067598A1 (en) * | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| US12194089B2 (en) * | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CA3167611A1 (en) * | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| US12351834B2 (en) * | 2020-03-03 | 2025-07-08 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| AU2021236068A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| TW202313967A (zh) | 2021-07-30 | 2023-04-01 | 美商亞克圖羅斯醫療公司 | Ｒｎａ疫苗 |
-
2021
- 2021-03-09 AU AU2021236068A patent/AU2021236068A1/en active Pending
- 2021-03-09 WO PCT/US2021/021572 patent/WO2021183563A1/en not_active Ceased
- 2021-03-09 CA CA3171231A patent/CA3171231A1/en active Pending
- 2021-03-09 EP EP21768525.4A patent/EP4117720A4/en active Pending
- 2021-03-09 CA CA3171219A patent/CA3171219A1/en active Pending
- 2021-03-09 US US17/196,889 patent/US11744887B2/en active Active
- 2021-03-09 JP JP2022554681A patent/JP2023517644A/ja active Pending
- 2021-03-09 TW TW110108383A patent/TW202200605A/zh unknown
- 2021-03-09 US US17/196,890 patent/US11759515B2/en active Active
- 2021-03-09 JP JP2022554368A patent/JP2023519173A/ja active Pending
- 2021-03-09 AU AU2021233816A patent/AU2021233816A1/en active Pending
- 2021-03-09 EP EP21767978.6A patent/EP4117725A4/en active Pending
- 2021-03-09 WO PCT/US2021/021573 patent/WO2021183564A1/en not_active Ceased
-
2023
- 2023-06-30 US US18/345,893 patent/US12220455B2/en active Active
- 2023-07-12 US US18/351,392 patent/US12390524B2/en active Active
-
2024
- 2024-12-04 US US18/969,110 patent/US20250161434A1/en active Pending
-
2025
- 2025-07-15 US US19/270,365 patent/US20260069677A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517644A5 (https=) | ||
| US12220455B2 (en) | Coronavirus vaccine compositions and methods | |
| US20230398076A1 (en) | Method of making lipid-encapsulated rna nanoparticles | |
| JP2024529975A5 (https=) | ||
| US12533318B2 (en) | Jet mixing lipid nanoparticle manufacturing process | |
| JP7774615B2 (ja) | 大型ｒｎａの脂質ナノ粒子封入 | |
| JP2024529975A (ja) | Ｒｎａワクチン | |
| JP2024542099A5 (https=) | ||
| IL302065A (en) | PAN-RAS mRNA CANCER VACCINES | |
| JP2024513048A (ja) | Ｒｎａの送達のための組成物及び方法 | |
| AU2021413753A1 (en) | Compositions and methods for delivery of rna | |
| JP2025503423A (ja) | ポリヌクレオチド組成物およびその使用 | |
| JP2025527583A (ja) | 脂質ナノ粒子の組成物 | |
| TW202438672A (zh) | 四價流感疫苗之方法及組成物 | |
| WO2024064886A1 (en) | Using n-terminal degrons to enhance rna t cell vaccine immunogenicity | |
| KR102956148B1 (ko) | 지질-캡슐화된 rna 나노입자 제조 방법 | |
| WO2026029847A1 (en) | Methods and compositions for pandemic influenza vaccine | |
| HK40110708A (zh) | Rna疫苗 | |
| HK40113162A (zh) | 多核苷酸组合物及其用途 | |
| BR112023004313B1 (pt) | Métodos para produção nanopartículas de rna encapsuladas em lipídeo |